Disease or Syndrome
Roche’s Gazyva Shows Promising Results in Phase 3 Lupus Nephritis Trial, Paving Way for Expanded Use
Gazyva, lupus nephritis, Roche, phase 3 trial, REGENCY study, obinutuzumab, kidney disease, autoimmune disease, treatment options.
Sanofi and Regeneron’s Dupixent Secures Historic FDA Approval as First Biologic Treatment for COPD
Dupixent, COPD, FDA Approval, Biologic Treatment, Sanofi, Regeneron
Gazyva Shows Promising Results in Lupus Nephritis Treatment, Paving Way for Expanded Indication
Gazyva, lupus nephritis, Roche, Genentech, Phase III REGENCY study, complete renal response, autoimmune disease, kidney function, end-stage kidney disease.
Transforming Multiple Sclerosis Treatment: Emerging Trends and Future Directions
Multiple sclerosis, high-efficacy treatments, stem cell transplantation, disease-modifying therapies, personalized medicine, AI integration, myelin repair, neurorestorative therapies.
Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta Globally Due to Safety Concerns
Pfizer, Oxbryta, sickle cell disease, global market withdrawal, safety concerns, clinical trials, vaso-occlusive crises, fatal events
Novo Nordisk’s Ozempic Expected to Face Medicare Price Negotiations in 2025
Ozempic, Medicare, price negotiations, Novo Nordisk, diabetes medication, Inflation Reduction Act
Amgen’s Mixed Results: A Tale of Two Readouts in Eczema and Myasthenia Gravis Trials
Amgen, Clinical Trials, Eczema, Myasthenia Gravis, Rocatinlimab, Uplizna, Biotechnology, Pharmaceutical Industry
FDA Approves IntraBio’s Aqneursa for Niemann-Pick Disease Type C, Marking Second Approval in a Week
IntraBio, Aqneursa, Niemann-Pick disease type C, FDA approval, rare neurodegenerative disease, levacetylleucine
UCB Expands Bimzelx Indications with Three New FDA Approvals for Chronic Inflammatory Diseases
Bimzelx, UCB, FDA approvals, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A, IL-17F inhibitor
UCB and Biogen Announce Positive Phase 3 Results for Dapirolizumab Pegol in Systemic Lupus Erythematosus, Plan Second Phase 3 Trial
UCB, Biogen, Dapirolizumab Pegol, Systemic Lupus Erythematosus, Phase 3 Trial, PHOENYCS GO, PHOENYCS FLY